9 Fev 2024 | Press release
Technophage, a biopharmaceutical company specializing in the development and production of biologics, particularly bacteriophage-based products, has officially announced the successful dosing of the first patient in this pivotal stage. The trial aims to assess the...
14 Dez 2023 | Press release
TechnoPhage, a clinical-stage biopharmaceutical company specializing in the development of phage treatments targeting specific pathogenic bacteria, has announced, following the successful conclusion of the Phase 1 study in 2022, the initiation of Phase 2b study...
4 Abr 2023 | Press release
Technophage is one of the co-promoters of the Bio-Hub Agenda – a National R&D Platform for Production, Commercialization and Distribution of Innovative Biopharmaceuticals – together with LxBio – Pharmaceuticals, VectorB2B – Drug...
16 Dez 2022 | Press release
TechnoPhage is proud to announce that the Phase I/IIa Clinical Trial of TP-102, a novel bacteriophage cocktail developed for the treatment of infected diabetic foot ulcers, has been successfully completed. This Clinical Trial was designed to evaluate the safety and...
12 Dez 2022 | Press release
TechnoPhage announced that it has provided TP-102, developed for the treatment of infected diabetic foot ulcers, for two compassionate use cases, which took place in July 2022, in Israel. The product was recently evaluated in the scope of the Phase I/IIa clinical...
23 Set 2022 | Press release
TechnoPhage announced the spin-off of T-Oncology AG, which will focus on the development of Antibody Drug Conjugates (ADCs), based on the proprietary Small Domain Antibodies platform (TechnoBodies), for the treatment of cancer. TechnoBodies technology has been...
